Physician profile
Mark D Johnson
NPI 1033198155
$1,258.69
in general payments reported to CMS, 2019-2025
12 companies · $285 in 2025
The $285 reported for 2025 was more than what 75% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $58.45 · 2021: $151 · 2022: $31.71 · 2023: $325 · 2024: $170 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $250.35 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Pregnyl |
| Ferring Pharmaceuticals INC. | $183.49 | 2019-2021 | |
| Becton, Dickinson and Company | $129.83 | 2025 | Bd Onclarity |
| Vertex Pharmaceuticals Incorporated | $120.36 | 2025 | |
| Roche Diagnostics Corporation | $106.07 | 2023 | Cobas 4800 Ct/Ng Test V2.0 |
| Myriad Women'S Health, INC. | $105.11 | 2023 | Genesight |
| Coopersurgical, INC. | $105.10 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $99.23 | 2019-2021 | |
| Emd Serono, INC. | $68.06 | 2020-2024 | |
| Hologic Sales and Service, LLC | $58.71 | 2021-2024 | Myosure Tissue Removal Device |
| Abbvie INC. | $17.95 | 2020 | |
| Genzyme Corporation | $14.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.